Envoy Medical Holds Shareholder Meeting

TL;DR

Envoy Medical held a shareholder vote on Nov 14th. Details TBD.

AI Summary

Envoy Medical, Inc. filed an 8-K on November 20, 2024, reporting a shareholder meeting held on November 14, 2024. The primary purpose of the meeting was for security holders to vote on matters presented by the company. Specific details regarding the proposals voted upon or the outcome of the vote were not provided in this filing excerpt.

Why It Matters

This filing indicates a formal shareholder engagement event, which is a standard corporate governance procedure. The outcomes of such meetings can influence company direction and shareholder rights.

Risk Assessment

Risk Level: low — The filing is a routine 8-K reporting a shareholder meeting, with no immediate financial or operational risks disclosed.

Key Players & Entities

• Envoy Medical, Inc. (company) — Registrant
• November 14, 2024 (date) — Date of earliest event reported
• November 20, 2024 (date) — Filing date

FAQ

Key Financial Figures

• $0.0001 — tered Class A Common Stock, par value $0.0001 per share COCH The Nasdaq Stock Mar
• $11.50 — A Common Stock at an exercise price of $11.50 per share COCHW The Nasdaq Stock Ma

Filing Documents

• ea0221887-8k_envoy.htm (8-K) — 45KB
• 0001213900-24-100544.txt ( ) — 261KB
• coch-20241114.xsd (EX-101.SCH) — 4KB
• coch-20241114_def.xml (EX-101.DEF) — 26KB
• coch-20241114_lab.xml (EX-101.LAB) — 36KB
• coch-20241114_pre.xml (EX-101.PRE) — 25KB
• ea0221887-8k_envoy_htm.xml (XML) — 6KB

07 Submission of Matters to a Vote of Security Holders

Item 5.07 Submission of Matters to a Vote of Security Holders. On November 14, 2024, Envoy Medical, Inc. (the "Company") held its 2024 Annual Meeting of Stockholders (the "Annual Meeting"). At the Annual Meeting: 1. The Company's stockholders (the "Stockholders") elected two Class I director nominees to the Company's Board of Directors to hold office until the earlier of the 2027 annual meeting of stockholders, the election of such director's successor, or such director's death, resignation or removal; 2. Stockholders ratified the appointment of Grant Thornton LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024; 3. Stockholders approved, on a non-binding and advisory basis, the compensation of the Company's named executive officers; and 4. Stockholders recommended, on a non-binding and advisory basis, a one-year frequency of votes on named executive officer compensation. The voting results for each such matter were as follows: 1. Election of directors: Nominee: For: Withheld: Broker Non-Votes: Michael Crowe 11,146,464 20,254 2,030,681 Mona Patel 11,047,146 119,572 2,030,681 2. Ratification of the appointment of Grant Thornton LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024: For: Against: Abstain: 13,173,556 12,662 11,181 3. Approval, on a non-binding and advisory basis, of the Company's named executive officer compensation: For: Against: Abstain: Broker Non-Votes: 11,117,644 29,673 19,401 2,030,681 4. Recommendation, on a non-binding and advisory basis, of a one-year frequency of votes on named executive officer compensation. 1 year 2 years 3 years Abstain Broker Non-Votes: 11,135,620 11,789 3,139 16,170 2,030,681 In light of stockholder approval at the Annual Meeting to hold an advisory vote on the compensation of the Company's named executive officers

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ENVOY MEDICAL, INC. November 20, 2024 By: /s/ David R. Wells David R. Wells Chief Financial Officer 2

View Full Filing

View this 8-K filing on SEC EDGAR